Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer
Status:
Recruiting
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
This research study is a two stage study which consists of a safety run-in phase and a
randomized phase 2 study which include subjects with previously-untreated, metastatic
pancreatic adenocarcinoma. In the run-in safety study, the safety of adding two formulations
(IV or Oral) of paricalcitol to a standard chemotherapy program of gemcitabine and
nab-paclitaxel will be evaluated. The randomized phase 2 study will evaluate the efficacy of
paricalcitol when added to gemcitabine and nab-paclitaxel
The drugs involved in this study are:
- Paricalcitol
- Gemcitabine
- Nab-paclitaxel
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
American Association for Cancer Research Lustgarten Foundation Stand Up To Cancer
Treatments:
Albumin-Bound Paclitaxel Ergocalciferols Gemcitabine Paclitaxel Vitamin D Vitamins